Search Results for "Sar240550"
21:31 EDT 23rd May 2013 | BioPortfolio
Original Source: Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer
Primary Objective: - To assess the objective response rate (ORR) of SAR240550 administered as a 60min intravenous infusion twice weekly or weekly, in combination with gemcitabine/carboplatin chemotherapy regimen in patients with metastatic Triple Negative Breast Cancer (mTNBC) Secondary Objectives: - To assess the clinical benefit rate (CBR) defined as the rate of complete response (CR), partial response (PR) and stable disease (SD) last...
Matching Channels
None
Matching News
None
Matching PubMed Articles
None
Search Whole site using Google
Loading
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
